The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Open accessAbstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline. RESULTS: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms. CONCLUSIONS: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status. CLASSIFICATION OF EVIDENCE: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although clinical trials of the Aβ-directed mAb Bapinezumab showed no clear cognitive benefits in patients with mild to moderate AD [42], the results also indicated that APOE ε4 carrier status may limit the response to anti-Aβ passive immunization [43,44], as well as being associated with an increased rate of microbleeds and vasogenic edema [45].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [44]
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [13]
In the citing paper
“in phase II trials, the anti-Aβ antibody bapineuzumab reduced CSF phospho-tau levels in patients with AD182,183”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [183]
In the citing paper
“In fact, there have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies (74-79).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Self-citationNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Self-citation
Cited by
Sorted by citations
Items 401–500 of 752
IgNAR antibody: Structural features, diversity and applications
Khalid, Z., Chen, Y., Du, Y., Abbas, M., Ma, H., Naz, Z., Mengist, H. M., Cao, M., & Jin, T. (2022) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2022.01.027 · Cited by 27
Grill, J. D., Raman, R., Ernstrom, K. B., Aisen, P. S. S., Dowsett, S. A., Chen, Y.-F., Liu‐Seifert, H., Hake, A. M., Miller, D. S., Doody, R. S., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0122-5 · Cited by 29
Self-citationIsolation and characterization of antibody fragments selective for toxic oligomeric tau
Tian, H., Davidowitz, E. J., Lopez, P. L. D. C., He, P., Schulz, P., Moe, J. G., & Sierks, M. R. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.002 · Cited by 27
Davis, P. R., Giannini, G., Rudolph, K., Calloway, N. T., Royer, C. M., Beckett, T. L., Murphy, M. P., Bresch, F., Pagani, D., Platt, T. L., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.09.007 · Cited by 26
Disease Modifying Drugs Targeting β-Amyloid
Ozudogru, S. N., & Lippa, C. F. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512452034 · Cited by 26
Deep brain stimulation: a novel strategy for treating Alzheimer's disease.
Lyketsos, C. G., Targum, S. D., Pendergrass, J. C., & Lozano, A. M. (2012) · Europe PMC (PubMed Central) · Cited by 25
Peripheral Routes to Neurodegeneration: Passing Through the Blood–Brain Barrier
Giannoni, P., Claeysen, S., Noè, F. M., & Marchi, N. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00003 · Cited by 25
Toly‐Ndour, C., Lui, G., Nunes, M. M., Bruley-Rosset, M., Aucouturier, P., & Dorothée, G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003953 · Cited by 27
Vaghari, D., Mohankumar, G., Tan, K., Lowe, A., Shering, C., Peter Tiňo, B., & Kourtzi, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-61355-3 · Cited by 24
The Diseased Brain and the Failing Mind
Zimmermann, M. (2020) · Bloomsbury Publishing Plc eBooks · doi:10.5040/9781350121836 · Cited by 29
Ludwig, J., Höffle‐Maas, A., Samochocki, M., Luttmann, E., Albuquerque, E. X., Fels, G., & Maelicke, A. (2010) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2010.505239 · Cited by 24
Antibody Therapy in Neurodegenerative Disease
Southwell, A. L., & Patterson, P. H. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.4.273 · Cited by 25
Greenberg, S. M., & Frosch, M. P. (2011) · Neurology · doi:10.1212/wnl.0b013e31820e7bce · Cited by 24
Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
Vukmir, R. B. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52042 · Cited by 24
Bobbins, A., Davies, M., Lynn, E., Roy, D., Yeomans, A., & Shakir, S. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70021 · Cited by 24
Grangeon, L., Quesney, G., Verdalle-Cazes, M., Coulette, S., Renard, D., Wacongne, A., Allou, T., Olivier, N., Boukriche, Y., Blanchet-Fourcade, G., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11145-4 · Cited by 23
Therapeutic anti‐amyloid β antibodies cause neuronal disturbances
Adhikari, U. K., Khan, R. H., Mikhael, M., Balez, R., David, M. A., Mahns, D. A., Hardy, J., & Tayebi, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12833 · Cited by 24
Szoeke, C. E. I., Robertson, J. S., Rowe, C. C., Yates, P. A., Campbell, K. E., Masters, C. L., Ames, D. J., Dennerstein, L., & Desmond, P. M. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.873394 · Cited by 24
Role of Biochemical Alzheimer's Disease Biomarkers as End Points in Clinical Trials
Siemers, E., Demattos, R. B., May, P. C., & Dean, R. A. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.85 · Cited by 23
Counts, S., Ray, B., Mufson, E. J., Perez, S. E., He, B., & Lahiri, D. K. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0020-9 · Cited by 24
Passive immunotherapy for Alzheimer's disease: What have we learned, and where are we headed?
Aisen, P. S. S., & Vellas, B. J. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0001-3 · Cited by 24
Güell‐Bosch, J., Lope‐Piedrafita, S., Esquerda‐Canals, G., Montoliu‐Gaya, L., & Villegas, S. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4263 · Cited by 21
Kou, J., Yang, J., Lim, J.-E., Pattanayak, A., Song, M., Planque, S. A., Paul, S., & Fukuchi, K.-I. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8691-z · Cited by 22
Clinical aspects of microbleeds in Alzheimer's disease
van der Flier, W. M. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.009 · Cited by 23
Minami, S., Sidahmed, E., Aïd, S., Shimoji, M., Niikura, T., Mocchetti, I., Rebeck, G. W., Prendergast, J., Dealwis, C. G., Wetzel, R. B., et al. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-57 · Cited by 26
Blockx, I., Einstein, S., Guns, P., Audekerke, J. V., Guglielmetti, C., Zago, W. M., Roose, D., Verhoye, M., der Linden, A. V., & Bard, F. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160023 · Cited by 23
Wang, S., Liu, J., Ji, W., Wen-Jiao, C. H. E. N., Fu, Q., Feng, L., & Ma, S. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60135-7 · Cited by 22
Beckmann, N., Doelemeyer, A., Zurbruegg, S., Bigot, K., Theil, D. J., Frieauff, W., Kolly, C., Moulin, P., Neddermann, D., Kreutzer, R., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.05.009 · Cited by 24
Majid, O., Cao, Y., Willis, B. A., Hayato, S., Takenaka, O., Lalovic, B. B., Reddy, S. H. S., Penner, N., Reyderman, L., Yasuda, S., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13224 · Cited by 21
Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy
Qu, L., Xu, S., Lan, Z., Fang, S., Xu, Y., & Zhu, X. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04449-1 · Cited by 22
Linton, A. E., Weekman, E. M., & Wilcock, D. M. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100030 · Cited by 21
Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE ε4 Carriers
Duits, F. H., Kester, M. I., Scheffer, P. G., Blankenstein, M. A., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122227 · Cited by 22
Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Cummings, J. L., & Zhong, K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.205 · Cited by 21
Li, Y., Liu, Y., Wang, Z., & Jiang, Y. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.838555 · Cited by 21
Zhang, R. Y., Leon, A. C., Chuang‐Stein, C., & Romano, S. J. (2011) · Clinical Trials · doi:10.1177/1740774510392255 · Cited by 21
Can novel therapeutics halt the amyloid cascade?
Prins, N. D., Visser, P. J., & Scheltens, P. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt28 · Cited by 20
Mandell, A. M., & Green, R. C. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch1 · Cited by 22
Harnessing the Immune System for Treatment and Detection of Tau Pathology
Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20
Immunotherapy for Alzheimer’s Disease
Farlow, M. R., & Brosch, J. R. (2013) · Neurologic Clinics · doi:10.1016/j.ncl.2013.03.012 · Cited by 20
Novel β-amyloid aggregation inhibitors possessing a turn mimic
Hamada, Y., Miyamoto, N., & Kiso, Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.02.016 · Cited by 20
Latest advances on interventions that may prevent, delay or ameliorate dementia
Wilson, D., Peters, R. K., Ritchie, K. A., & Ritchie, C. W. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310397636 · Cited by 20
Tachi, N., Hashimoto, Y., & Matsuoka, M. (2012) · Biochemical Journal · doi:10.1042/bj20100993 · Cited by 20
Fowler, K. D., Funt, J. M., Artyomov, M. N., Zeskind, B. J., Kolitz, S. E., & Towfic, F. (2015) · Scientific Reports · doi:10.1038/srep14324 · Cited by 19
Modern Lifestyle Diseases: Chronic Diseases, Awareness and Prevention
Senapati, S., Bharti, N., & Bhattacharya, A. (2015) · Cited by 20
Zhang, L., Xu, J., Gao, J., Chen, P., Yin, M., & Zhao, W. (2019) · Immunity & Ageing · doi:10.1186/s12979-018-0142-7 · Cited by 20
AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials
Vellas, B. J., Pesce, A., Robert, P. H., Aisen, P. S. S., Ancoli‐Israel, S., Andrieu, S., Cedarbaum, J. M., Dubois, B., Siemers, E., Spire, J., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.2020 · Cited by 20
Clinical implications of extracellular vesicles in neurodegenerative diseases
Vinaiphat, A., & Sze, S. K. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1657407 · Cited by 20
PET Imaging in Preclinical Anti-Aβ Drug Development
Syvänen, S., Meier, S. R., Roshanbin, S., Xiong, M., Faresjö, R., Gustavsson, T., Bonvicini, G., Schlein, E., Aguilar, X., Julku, U. H., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03277-z · Cited by 20
The Immune System as a Therapeutic Target for Alzheimer’s Disease
Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 19
When Will Alzheimer's Disease be Cured? A Pharmaceutical Perspective
Townsend, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110020 · Cited by 19
Darby, D., Brodtmann, A. G., Woodward, M., Budge, M. M., & Maruff, P. T. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000354 · Cited by 19
Bruley-Rosset, M., Lui, G., Dansokho, C., Chaigneau, T., & Dorothée, G. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0317-5 · Cited by 19
Xu, X., Samtani, M. N., Yuan, M., & Nandy, P. (2014) · AAPS Journal · doi:10.1208/s12248-014-9655-y · Cited by 18
APOE Genotype in the Diagnosis of Alzheimer’s Disease in Patients With Cognitive Impairment
Sun, X., Nicholas, J. S., Walker, A., Wagner, M. T., & Bachman, D. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512452037 · Cited by 20
Marsool, M. D. M., Prajjwal, P., Reddy, Y. B., Marsool, A. D. M., Lam, J. R., & Nandwana, V. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101547 · Cited by 18
Kang, J., Ryoo, N., Shin, D. W., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.6.447 · Cited by 18
Arai, H., Umemura, K., Ichimiya, Y., Iseki, E., Eto, K., Miyakawa, K., Kirino, E., Shibata, N., Baba, H., & Tsuchiwata, S. (2015) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12516 · Cited by 19
Leclerc, B., & Abulrob, A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/589308 · Cited by 18
APOE ε4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics
Kaufer, D., & Gandy, S. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c6784a · Cited by 21
Schnabel, J. (2011) · Nature · doi:10.1038/475s18a · Cited by 17
Janssens, J., Hermans, B., Vandermeeren, M., Barale-Thomas, E., Borgers, M., Willems, R., Meulders, G., Wintmolders, C., den Bulck, D. V., Bottelbergs, A., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105365 · Cited by 18
Meyer‐Luehmann, M., Mora, J. R., Mielke, M. L., Spires‐Jones, T. L., de Calignon, A., von Andrian, U. H., & Hyman, B. T. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-22 · Cited by 17
New treatment modalities in Alzheimer's disease
Köseoğlu, E. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i14.1764 · Cited by 17
Guo, X., Liu, Y., Morgan, D., & Zhao, L. (2020) · Aging and Disease · doi:10.14336/ad.2020.0201 · Cited by 16
Current status of vaccination therapies in Alzheimer's disease
Karran, E. H. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12009 · Cited by 16
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
A review of therapeutic failures in late-stage clinical trials
Jain, R., Subramanian, J., & Rathore, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161366 · Cited by 18
Counts, S., Perez, S. E., He, B., & Mufson, E. J. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140812114037 · Cited by 18
Therapeutic Antibodies for Brain Disorders
Paul, S. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002620 · Cited by 16
Beierlein, J. M., McNamee, L. M., Walsh, M. J., & Ledley, F. D. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.003 · Cited by 17
Bapineuzumab, an investigational agent for Alzheimer's disease.
Khorassani, F., & Hilas, O. (2013) · Europe PMC (PubMed Central) · Cited by 16
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 16
Koh, E.-K., Yun, W.-B., Kim, J.-E., Song, S., Sung, J.-E., Lee, H. A., Seo, E.-J., Jee, S. W., Bae, C.-J., & Hwang, D. Y. (2016) · Laboratory Animal Research · doi:10.5625/lar.2016.32.2.105 · Cited by 16
Harnessing MerTK agonism for targeted therapeutics
Kedage, V., Ellerman, D. A., Chen, Y., Liang, W., Borneo, J., Wu, Y., & Yan, M. (2019) · mAbs · doi:10.1080/19420862.2019.1685832 · Cited by 15
Wang, Y., Yu, Q., Chen, B., Zhou, J., Li, Z., Liao, W., Liu, J., & Yang, A. (2025) · BMC Neurology · doi:10.1186/s12883-025-04302-5 · Cited by 15
Lyu, D., Lyu, X., Huang, L. T., & Fang, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101959 · Cited by 14
Therapeutic Potential of Vaccines for Alzheimer‘s Disease
Shah, S., & Federoff, H. J. (2011) · Immunotherapy · doi:10.2217/imt.10.94 · Cited by 15
Recent advances in the development of immunotherapies for tauopathies
Ubhi, K. K., & Masliah, E. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.10.007 · Cited by 16
Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
Moreth, J., Mavoungou, C., & Schindowski, K. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00025 · Cited by 15
Adverse events and dropouts in Alzheimer's disease studies: What can we learn?
Henley, D. B., Sundell, K. L., Sethuraman, G., & Schneider, L. S. S. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.11.008 · Cited by 17
Mihăescu, R., Detmar, S. B., Cornel, M. C., van der Flier, W. M., Heutink, P., Hol, E. M., Rikkert, M. G. M. O., van Duijn, C. M., & Janssens, A. C. J. W. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1410 · Cited by 15
Xing, H., Li, B., Peng, D., Wang, C., Wang, G., Li, P., Le, Y., Wang, J., Ye, G., & Chen, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180076 · Cited by 15
Should development of Alzheimer¿s disease-specific intravenous immunoglobulin be considered?
Loeffler, D. A. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0198-z · Cited by 15
Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?
Farlow, M. R. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt39 · Cited by 14
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 15
Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease
Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 17
Jeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2025) · Journal of Medical Internet Research · doi:10.2196/68454 · Cited by 18
Lyketsos, C. G., Holroyd, K., Fosdick, L., Smith, G. S., Leoutsakos, J., Munro, C. A., Oh, E. S., Drake, K. E., Rosenberg, P., Anderson, W. S., et al. (2015) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s81542 · Cited by 15
Self-citationImmune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit
von Geldern, G., McPharlin, T. O., & Becker, K. J. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0096-3 · Cited by 14
Romero, K., Corrigan, B., Neville, J., Kopko, S., & Cantillon, M. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.51 · Cited by 14
Kavanagh, S., Howe, I., Brashear, H. R., Wang, D., van Baelen, B., Todd, M., & Schwalen, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256044 · Cited by 14
Winkler, D. T., Abramowski, D., Danner, S., Zurini, M. G. M., Paganetti, P., Tolnay, M., & Staufenbiel, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.030 · Cited by 14
New Age Therapy for Alzheimer’s Disease by Neuronal Network Reconstruction
Tohda, C. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00438 · Cited by 14
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
Kayed, R., Castillo‐Carranza, D. L., & Guerrero‐Munoz, M. J. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s40131 · Cited by 16
Tanaka, K., Nishimura, M., Yamaguchi, Y., Hashiguchi, S., Takiguchi, S., Yamaguchi, M., Tahara, H., Gotanda, T., Abe, R., Ito, Y., et al. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.04.010 · Cited by 14
Greenberg, S. M., Rapalino, O., & Frosch, M. P. (2010) · New England Journal of Medicine · doi:10.1056/nejmcpc1004364 · Cited by 14
Testing the amyloid hypothesis of Alzheimer's disease in vivo
Gandy, S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70055-7 · Cited by 15
Vascular Considerations for Amyloid Immunotherapy
Foley, K. E., & Wilcock, D. M. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01235-1 · Cited by 13
Hao, Y., Dong, M., Sun, Y., Duan, X., & Niu, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1147757 · Cited by 13
Metadata
- Authors
- Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., Mulnard, R., Barakos, J., Gregg, K. M., Liu, E., Lieberburg, I., Schenk, D., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Butler Hospital (S.S.), Providence, RI; Brigham & Women's Hospital (R.S.), Boston, MA; University of Michigan (S.G.), Ann Arbor; UCL (N.C.F.), Institute of Neurology, London, UK; University of Göteborg (K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; VA Medical Center (M.R.), Seattle, WA; Cleo Roberts Center for Clinical Research/Sun Health Research Institute (M.S.), Sun City, AZ; Columbia University (L.S.H.), New York, NY; Baylor College of Medicine (R.D.), Houston, TX; Yale...
- Venue
- Neurology
- Published
- 2009-12-15
- Volume
- 73
- Issue
- 24
- Pages
- 2061-2070
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2790221
- OpenAlex
- W2086572083
- Cited by
- 753
- References
- 40
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 34 · 2021: 21 · 2020: 30 · 2019: 30 · 2018: 26 · 2017: 30 · 2016: 45 · 2015: 52 · 2014: 71 · 2013: 78 · 2012: 91
- FWCI
- 55.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Pfizer
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institutes of Health (5r03ag023916-02, 5r01ag007370-30, 1r41ns056856-01a2, 5u01ag024904-10)
- U.S. Public Health Service (UO1AGO24904)
- National Institute on Alcohol Abuse and Alcoholism (RL1AA017536)
- National Institute on Aging (U01-AG-024904, R01AG030457, R01AG14763, AG 08671, 1-R01-AG030457-01A1, P01AG007232, R01AG026114, U01AG016976, R01-AG007370, R43AG033474, U01AG010483, U01-AG 16976, 1-UO1-AG024904, 1 R03 AG023916-01A1, P01AG030004, P50AG008702, R01AG027435, R01AG017761, P01AG07232, P50AG008671, P30AG019610, P30 P3-AG 019610, P50AG005136, P50AG005134, U01AG032438, P50 AG08671, 5-U01-AG10483, AG06036-13, P50AG08702)
- National Heart, Lung, and Blood Institute (R01HL091099)
- National Institute of Mental Health (1 R01 MH58620-01A2, P50MH068789, R01MH058620)
- National Institute of Diabetes and Digestive and Kidney Diseases (IR21DK062098)
- National Institute of Neurological Disorders and Stroke (P01 NS 15655, P01NS015655, R01NS042859, T32NS007224)
- National Center for Research Resources (U54RR024350-01, P20RR020626)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, amyloid-beta, vasogenic edema, APOE ε4 carriers, cognitive decline, functional decline, dose escalation, treatment efficacy, drug safety
- MeSH terms
- Aged, Alzheimer Disease, Antibodies, Monoclonal, Brain, Brain Edema, Cognition, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Magnetic Resonance Imaging, Male, Severity of Illness Index, Biomarkers, Treatment Outcome, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
